Abattis Biologix Corporation was founded in 2009 and assembled a team of like minded people who shared a vision of making a difference and helping. We all feel that there is a growing global need for a nature based solution to viral infection. We seek to give back and offer aid through the commercialization of two latter stage highly effective natural botanical antiviral products. These antiviral formulations have been tested and proven effective against the effects of viral infections such as influenza and it’s many mutated forms; Swine, Bird and SARS are a few common examples.

$9 million (US) has been spent to date and it has taken many years of research, development and testing to get the Abattis formulation to this stage. Current world developments have highlighted the need for this formulation today and Abattis intends to be prepared to meet this need. In an effort to keep costs as low as possible the company has retained a core of management who will be paid upon success and a group of share induced directors and advisors to ensure we have the expertise to reach and exceed our long term goals. With current financial markets and world attention focused on the growing FLU pandemic, Abattis feels that our company offers a lower risk investment opportunity within a socially responsible, ethically motivated company. With the testing we have completed to date we are confident that following our business plan will allow Abattis to be a very well known, loved and respected name in the near future.

Abattis has acquired full rights, patents and title to a platform technology comprised of a group of synergistically active antiviral compounds (the “Abattis Platform” or the “Platform”), and two commercial-ready products developed from the technology for use with animals and humans. Both are highly effective and non-toxic broad spectrum antiviral treatments designed to provide a multi-pronged attack against human and animal strains of influenza.